Skip to main content

Advertisement

SpringerLink
Log in

Author’s response to “Letter to the editor: unvalidated antibodies and misleading results”

  • Rebuttal Letter
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figs. 1–3
Fig. 4
Figs. 5–7

References

  1. Muenst S, Schaerli AR, Gao F, Daster S, Trella E, Droeser RA, Muraro MG, Zajac P, Zanetti R, Gillanders WE, Weber WP, Soysal SD (2014) Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat. doi:10.1007/s10549-014-2988-5

    Google Scholar 

  2. Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M, Herbst RS, Gettinger SN, Chen L, Rimm DL (2014) Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest 94(1):107–116. doi:10.1038/labinvest.2013.130

    Article  CAS  PubMed  Google Scholar 

  3. Muenst S, Soysal SD, Gao F, Obermann EC, Oertli D, Gillanders WE (2013) The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat 139(3):667–676. doi:10.1007/s10549-013-2581-3

    Article  CAS  PubMed  Google Scholar 

  4. Schalper KA, Velcheti V, Carvajal D, Wimberly H, Brown J, Pusztai L, Rimm DL (2014) In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res 20(10):2773–2782. doi:10.1158/1078-0432.CCR-13-2702

    Article  CAS  PubMed  Google Scholar 

  5. Ghebeh H, Mohammed S, Al-Omair A, Qattan A, Lehe C, Al-Qudaihi G, Elkum N, Alshabanah M, Bin Amer S, Tulbah A, Ajarim D, Al-Tweigeri T, Dermime S (2006) The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 8(3):190–198. doi:10.1593/neo.05733

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Ghebeh H, Tulbah A, Mohammed S, Elkum N, Bin Amer SM, Al-Tweigeri T, Dermime S (2007) Expression of B7-H1 in breast cancer patients is strongly associated with high proliferative Ki-67-expressing tumor cells. Int J Cancer 121(4):751–758. doi:10.1002/ijc.22703

    Article  CAS  PubMed  Google Scholar 

  7. Hino R, Kabashima K, Kato Y, Yagi H, Nakamura M, Honjo T, Okazaki T, Tokura Y (2010) Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 116(7):1757–1766. doi:10.1002/cncr.24899

    Article  PubMed  Google Scholar 

  8. Mu CY, Huang JA, Chen Y, Chen C, Zhang XG (2011) High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol 28(3):682–688. doi:10.1007/s12032-010-9515-2

    Article  CAS  PubMed  Google Scholar 

  9. Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, Sengupta S, Frank I, Parker AS, Zincke H, Blute ML, Sebo TJ, Cheville JC, Kwon ED (2006) Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 66(7):3381–3385. doi:10.1158/0008-5472.CAN-05-4303

    Article  CAS  PubMed  Google Scholar 

  10. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, Higuchi T, Yagi H, Takakura K, Minato N, Honjo T, Fujii S (2007) Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA 104(9):3360–3365. doi:10.1073/pnas.0611533104

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. Ohigashi Y, Sho M, Yamada Y, Tsurui Y, Hamada K, Ikeda N, Mizuno T, Yoriki R, Kashizuka H, Yane K, Tsushima F, Otsuki N, Yagita H, Azuma M, Nakajima Y (2005) Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 11(8):2947–2953. doi:10.1158/1078-0432.CCR-04-1469

    Article  CAS  PubMed  Google Scholar 

  12. Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, Nakamura S, Enomoto K, Yagita H, Azuma M, Nakajima Y (2007) Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 13(7):2151–2157. doi:10.1158/1078-0432.CCR-06-2746

    Article  CAS  PubMed  Google Scholar 

  13. Wu C, Zhu Y, Jiang J, Zhao J, Zhang XG, Xu N (2006) Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem 108(1):19–24. doi:10.1016/j.acthis.2006.01.003

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Pathology, University Hospital Basel, Schönbeinstrasse 40, 4032, Basel, Switzerland

    S. Muenst & A. Tzankov

  2. Department of Surgery, University Hospital Basel, Basel, Switzerland

    S. D. Soysal

  3. Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA

    W. E. Gillanders

Authors
  1. S. Muenst
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Tzankov
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W. E. Gillanders
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. D. Soysal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Muenst.

Additional information

This rebuttal letter refers to the article availbale at doi:10.1007/s10549-014-3061-0.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Muenst, S., Tzankov, A., Gillanders, W.E. et al. Author’s response to “Letter to the editor: unvalidated antibodies and misleading results”. Breast Cancer Res Treat 147, 459–462 (2014). https://doi.org/10.1007/s10549-014-3064-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-014-3064-x

Keywords

Search

Navigation